Abstract
Amylin is a 37-amino acid peptide hormone that is co-secreted with insulin by pancreatic B cells in response to food intake. Exogenous amylin potently and dosedependently reduces feeding in rats and mice, with both central and peripheral sites being effective. Although amylin has been characterized as a satiety signal that regulates short-term food intake (i.e., meal size), recent data indicate that amylin may have long term effects on food intake and body weight. In fact, amylin shares many properties with the established adiposity signals, leptin and insulin. Like leptin and insulin, amylin is not synthesized within the brain, but is rapidly and efficiently transported across the blood-brain barrier (BBB) to a variety of discrete brain regions, including the hypothalamus, where populations of amylin binding sites are found. Further, amylin secretion and plasma levels are correlated with the degree of body adiposity, as is the case for leptin and insulin. In the following brief review, a summary of the findings from recent reports is presented supporting the hypothesis that amylins role in the control of food intake is not limited to that of purely a satiety signal that brings individual bouts of ingestion to an end, but also serves as an adiposity signal acting within the brain to regulate long-term energy homeostasis.
Keywords: Hormone, ingestion, obesity, satiety, peptide, food intake
Current Pharmaceutical Design
Title: Central Amylin Signaling and the Regulation of Energy Homeostasis
Volume: 9 Issue: 10
Author(s): Paul A. Rushing
Affiliation:
Keywords: Hormone, ingestion, obesity, satiety, peptide, food intake
Abstract: Amylin is a 37-amino acid peptide hormone that is co-secreted with insulin by pancreatic B cells in response to food intake. Exogenous amylin potently and dosedependently reduces feeding in rats and mice, with both central and peripheral sites being effective. Although amylin has been characterized as a satiety signal that regulates short-term food intake (i.e., meal size), recent data indicate that amylin may have long term effects on food intake and body weight. In fact, amylin shares many properties with the established adiposity signals, leptin and insulin. Like leptin and insulin, amylin is not synthesized within the brain, but is rapidly and efficiently transported across the blood-brain barrier (BBB) to a variety of discrete brain regions, including the hypothalamus, where populations of amylin binding sites are found. Further, amylin secretion and plasma levels are correlated with the degree of body adiposity, as is the case for leptin and insulin. In the following brief review, a summary of the findings from recent reports is presented supporting the hypothesis that amylins role in the control of food intake is not limited to that of purely a satiety signal that brings individual bouts of ingestion to an end, but also serves as an adiposity signal acting within the brain to regulate long-term energy homeostasis.
Export Options
About this article
Cite this article as:
Rushing A. Paul, Central Amylin Signaling and the Regulation of Energy Homeostasis, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455387
DOI https://dx.doi.org/10.2174/1381612033455387 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Current Diabetes Reviews The Effect of Dual-Task Testing on Balance and Gait Performance in Adults with Type 1 or Type 2 Diabetes Mellitus: A Systematic Review
Current Diabetes Reviews The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Editorial [Hot Topic: Inflammation in Atherosclerosis: Current Therapeutic Approaches (Executive Guest Editor: Dimitris Tousoulis)]
Current Pharmaceutical Design Novel Peptides under Development for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men
Current Pharmaceutical Design Advances in the Topical Treatment of Diabetic Foot Ulcers
Current Diabetes Reviews Turning Up the Pressure on Vascular Disease
Current Neurovascular Research p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews Novel Therapeutic Strategies Targeting Vascular Redox in Human Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Current Status of Knowledge and Awareness of Diabetes Mellitus in Saudi Arabia
Current Diabetes Reviews Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Role of Vitamin D in the Pathophysiology and Treatment of Type 2 Diabetes
Current Diabetes Reviews Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research
Current Diabetes Reviews Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets